Fecal microbiota transplant (FMT) has emerged as an effective and increasingly popular therapy for recurrentClostridium difficileinfections in patients that have failed standard antimicrobial treatment. Patient access to FMT is hampered by the logistics of manufacturing, storing, and delivering the inocula. An observational study describes the development and clinical efficacy of freeze-dried FMT capsules for oral administration. While awaiting the emergence of defined bacterial therapeutics forClostridium difficileinfections, this refinement of FMT is an encouraging step toward simplifying FMT treatment. Randomized controlled trials are required to further establish the efficacy and safety of lyophilized FMT.
1Division of Pediatrics, Assaf-Harofeh Medical Center, Zerifin, Israel
2Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
3Boston Children’s Hospital, Boston, MA, USA
4Edward Hines Jr. Veterans Affairs Hospital, Hines, IL, USA
Correspondence: Ilan Youngster, MD, MMSc, Division of Pediatrics, Assaf Harofeh Medical Center, Zerifin 70300, Israel. E-mail: email@example.com
Received 02 February 2017; accepted 02 February 2017
Guarantor of the article: Ilan Youngster, MD, MMSc.
Specific author contributions: I.Y. collected data and wrote the initial draft of the manuscript. D.N.G. revised and drafted the manuscript. Both authors have approved the final draft as submitted.
Financial support: None.
Potential competing interests: None.